
|Videos|October 26, 2017
Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer
Author(s)Leena Gandhi, MD, PhD
Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).
Advertisement
Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non—small cell lung cancer (NSCLC).
Gandhi says that there is clear-cut evidence of the superiority of alectinib over crizotinib (Xalkori). Results from the J-ALEX and ALEX trials showed improved long-term outcomes systemically with alectinib, and in the central nervous system (CNS), as well.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































